Search Within

Renier J Brentjens

  1. "MSK Grad Students"
Formats
  1. Journal Article (14)
  2. Meeting Abstract (13)
  3. Review (1)
Groups
  1. Adult Leukemia (28)
  2. Center for Hematologic Malignancies (28)
  3. Department of Medicine (28)
  4. GSK Faculty (28)
  5. Hematologic Malignancies Research (28)
  6. Hematologic Malignancies, Division of (28)

More Groups

People
  1. Craig Sauter (14)
  2. Maria Palomba (14)
  3. Miguel-Angel Perales (14)
  4. Gunjan Shah (13)
  5. Jae Park (13)
  6. Michael Scordo (13)

More People

Years
  1. 2025 (1)
  2. 2023 (2)
  3. 2022 (1)
  4. 2021 (4)
  5. 2020 (12)
  6. 2019 (6)

More Years

Publications
  1. Blood (8)
  2. Blood Advances (3)
  3. Cancer Cell (2)
  4. Cancer Immunology Research (2)
  5. Molecular Therapy (2)
  6. Nature Communications (2)

More Publications

Publishers
  1. American Society of Hematology (11)
  2. Nature Publishing Group (8)
  3. American Association for Cancer Research (2)
  4. Cell Press (2)
  5. Elsevier Inc. (2)
  6. American Society of Clinical Oncology (1)

More Publishers

Results (28)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • EZH2 inhibition enhances T cell immunotherapies by inducing lymphoma immunogenicity and improving T cell function
    Journal Article

    Isshiki, Y.; Chen, X.; Teater, M.; Karagiannidis, I.; Nam, H.; Cai, W.; Meydan, C.; Xia, M.; Shen, H.; Gutierrez, J.; more...
    Cancer Cell (2025)

    Fulltext@MSK | Save
  • A phase II trial of prophylactic anakinra to prevent neurotoxicity in patients receiving anti-CD19 CAR T-cell therapy for relapsed or refractory lymphoma: Final results from cohort 2
    Meeting Abstract

    Nath, K.; Devlin, S. M.; Sauter, C. S.; Palomba, M. L.; Shah, G. L.; Dahi, P. B.; Lin, R. J.; Scordo, M.; Perales, M. A.; Leslie, L. A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: Phase 2 trial interim results
    Journal Article

    Park, J. H.; Nath, K.; Devlin, S. M.; Sauter, C. S.; Palomba, M. L.; Shah, G.; Dahi, P.; Lin, R. J.; Scordo, M.; Perales, M. A.; more...
    Nature Medicine (2023)

    Fulltext@MSK | Save
  • Engineering CAR-T cells to activate small-molecule drugs in situ
    Journal Article

    Gardner, T. J.; Lee, J. P.; Bourne, C. M.; Wijewarnasuriya, D.; Kinarivala, N.; Kurtz, K. G.; Corless, B. C.; Dacek, M. M.; Chang, A. Y.; Mo, G.; more...
    Nature Chemical Biology (2022)

    Fulltext@MSK | Save
  • Five-year experience using bridging radiotherapy prior to chimeric antigen receptor (CAR) T-cell therapies for B-cell malignancies at Memorial Sloan Kettering Cancer Center
    Meeting Abstract

    Silverman, E. A.; Hubbeling, H.; Palomba, M. L.; Wijetunga, N. A.; Tringale, K.; Lebow, E.; Tomas, A. A.; Shouval, R.; Batlevi, C. L.; Brentjens, R. J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Lesion characteristics and patterns of failure in diffuse large B cell lymphoma patients treated with bridging radiotherapy prior to chimeric antigen receptor T cell therapy
    Meeting Abstract

    Hubbeling, H.; Silverman, E. A.; Wijetunga, N. A.; Palomba, M. L.; Tringale, K.; Lebow, E.; Tomas, A. A.; Shouval, R.; Batlevi, C. L.; Brentjens, R. J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells
    Journal Article

    Pennisi, M.; Sanchez-Escamilla, M.; Flynn, J. R.; Shouval, R.; Alarcon Tomas, A.; Silverberg, M. L.; Batlevi, C.; Brentjens, R. J.; Dahi, P. B.; Devlin, S. M.; more...
    Blood Advances (2021)

    Fulltext@MSK | Save
  • Cytokine IL-36γ improves CAR T-cell functionality and induces endogenous antitumor response
    Journal Article

    Li, X.; Daniyan, A. F.; Lopez, A. V.; Purdon, T. J.; Brentjens, R. J.
    Leukemia (2021)

    Fulltext@MSK | Save
  • International prognostic index predicts outcomes in patients with relapsed and refractory large diffuse B cell lymphoma treated with commercial CAR T cells
    Meeting Abstract

    Garcia-Recio, M.; Wudhikarn, K.; Pennisi, M.; Alonso-Trillo, R.; Flynn, J.; Roni, S.; Batlevi, Y.; Silverberg, M. L.; Batlevi, C. W.; Brentjens, R.; more...
    Bone Marrow Transplantation (2020)

    Fulltext@MSK | Save
  • Tumor derived UBR5 promotes ovarian cancer growth and metastasis through inducing immunosuppressive macrophages
    Journal Article

    Song, M.; Yeku, O. O.; Rafiq, S.; Purdon, T.; Dong, X.; Zhu, L.; Zhang, T.; Wang, H.; Yu, Z.; Mai, J.; more...
    Nature Communications (2020)

    Fulltext@MSK | Save